Navigation Links
Encision Reports Profitable First Fiscal Quarter Results
Date:7/30/2009

BOULDER, Colo., July 30 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first quarter of fiscal year 2010.

Net sales for the three-months ended June 30, 2009 totaled $3.2 million, representing a 3% increase over net sales of $3.1 million for the prior fiscal year's first quarter. The Company recorded net income of $163 thousand or $.03 per share for the first quarter of fiscal year 2010, compared to a net loss of $164 thousand or ($.03) per share for the first quarter of fiscal year 2009. Gross profit margin for the first quarter of fiscal year 2010 was 64%, as compared to 60.3% for the first quarter of fiscal year 2009, a 3.7% increase resulting from production efficiencies and an increase to inventory which resulted in a higher absorption of overhead costs to inventory and a decrease to cost of sales.

"We are pleased with the start to our first quarter of fiscal year 2010, especially with the turnaround from last year's first quarter net loss. Net income increased from last year's first quarter net loss as a result of a slight increase in sales income, increased gross profit margin and reduced operating expenses," said Jack Serino, President and CEO of Encision Inc.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

                                  Encision Inc.
                            Condensed Balance Sheets
                             (Amounts in thousands)

                                            June 30,     March 31,
                                             2009         2009
                                          (Unaudited)   (Audited)
                                          -----------   ---------
    ASSETS
    Cash and cash equivalents                $126          $85
    Accounts receivable, net                1,235        1,264
    Inventories, net                        2,459        2,505
    Prepaid expenses                          110           36
                                              ---           --
      Total current assets                  3,930        3,890
                                            -----        -----
    Equipment, net                            884          840
    Patents, net                              223          216
    Other assets                               18           24
                                               --           --
      Total assets                         $5,055       $4,970
                                           ------       ------
    LIABILITIES AND SHAREHOLDERS'
     EQUITY
    Accounts payable                         $662         $745
    Accrued compensation                      311          406
    Other accrued liabilities                 360          367
    Line of credit                            275          191
                                              ---          ---
      Total current liabilities             1,608        1,709
                                            -----        -----
    Common stock and additional
     paid-in capital                       19,582       19,560
    Accumulated (deficit)                 (16,135)     (16,299)
                                          -------      -------
      Total shareholders' equity            3,447        3,261
                                            -----        -----
      Total liabilities and
       shareholders' equity                $5,055       $4,970
                                           ------       ------


                                  Encision Inc.
                     Condensed Statements of Operations
             (Amounts in thousands, except per share information)

                                                 (Unaudited)
                                              Three Months Ended
                                              ------------------
                                            June 30,       June 30,
                                              2009           2008
                                            --------       --------
    Net sales                               $3,174         $3,094
    Cost of sales                            1,142          1,229
                                             -----          -----
    Gross profit                             2,032          1,865
                                             -----          -----
    Operating expenses:
      Sales and marketing                    1,199          1,374
      General and administrative               354            367
      Research and development                 301            289
                                               ---            ---
       Total operating expenses              1,854          2,030
                                             -----          -----
    Operating income (loss)                    178           (165)
    Interest and other income
     (expense), net                            (15)             1
                                               ---            ---
    Income (loss) before provision
     for income taxes                          163           (164)
    Provision for income taxes                   -              -
                                               ---            ---
    Net income (loss)                         $163          $(164)
                                              ====          =====
    Net income (loss) per
     share-basic and diluted                 $0.03         $(0.03)
    Basic and diluted weighted
     average number of shares                6,455          6,450


'/>"/>
SOURCE Encision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
2. Encision Announces Quoting of Common Stock on the OTC Bulletin Board
3. Encision Pursues Transfer of Quotation to OTC Bulletin Board
4. Encision Reports First Fiscal Quarter Results
5. Encision Reports Fourth Quarter and Fiscal Year 2008 Results
6. Encision Moves Power and Safety to Surgeons Fingertips
7. Encision Supports National Patient Safety Awareness Week
8. Encision Reports Third Fiscal Quarter Results
9. American Stock Exchange Accepts Encisions Plan to Regain Compliance
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: